exporting, directly or indirectly dealing in pharmaceutical products, compound or formulation containing Vildagliptin alone or Vildagliptin + Metformin Hydrochloride in combination or Vildagliptin in combination with ... stock of infringing pharmaceutical formulations, compound or combinations comprising Vildagliptin alone and/or Vildagliptin in combination with Metformin Hydrochloride or any other compound or formulation
indirectly dealing in Active Pharmaceutical Ingredient (API), pharmaceutical products, or formulations containing Vildagliptin alone or Vildagliptin in combination with any other compound ... manufacture and sale of infringing pharmaceutical products or formulation or combination containing Vildagliptin alone or Vildagliptin in combination in any form and a decree
directly or indirectly active pharmaceutical ingredient (API), pharmaceutical products or formulations containing Vildagliptin alone or Vildagliptin + Metformin Hydrochloride in comination or Vildagliptin in combination with ... defendant, in the event of manufacture and sale of any Vildagliptin API or infringing pharmaceutical products or formulation containing Vildagliptin alone or Vildagliptin + Metformin Hydrochloride
indirectly dealing in Active Pharmaceutical Ingredient (API), Pharmaceutical products, or formulation containing Vildagliptin alone or Vildagliptin in combination with any other compound ... stock of infringing pharmaceutical formulations, compound of combinations comprising Vildagliptin alone and/or Vidagliptin in combination with any other compound or formulation available with
exporting, directly or indirectly dealing in pharmaceutical products, compound or formulation containing Vildagliptin alone or Vildagliptin + Metformin Hydrochloride in combination or Vildagliptin in combination with ... stock of infringing pharmaceutical formulations, compound or combinations comprising Vildagliptin alone and/or Vildagliptin in combination with Metformin Hydrochloride or any other compound or formulation
indirectly dealing in active pharmaceutical ingredient (API), pharmaceutical products or formulations containing Vildagliptin alone or Vildagliptin in combination with any other compound ... defendants, in the event of manufacture and sale of any Vildagliptin API or infringing pharmaceutical products or formulation containing Vildagliptin alone or Vildagliptin with
product and New Chemical Entity (NCE), assigned International Non-Proprietary Name (INN) Vildagliptin. The petitioner is said to operate in India through its subsidiary which ... markets patented product Vildagliptin in India. The petitioner claims to have spent substantial financial resources on pharmaceutical research and development in order to invent
